- Home
- CSTL vs KURA Comparison
CSTL vs KURA Comparison
Compare CSTL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- KURA
- Stock Information
- Founded
- CSTL 2007
- KURA 2014
- Country
- CSTL United States
- KURA United States
- Employees
- CSTL N/A
- KURA N/A
- Industry
- CSTL Medical Specialities
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSTL Health Care
- KURA Health Care
- Exchange
- CSTL Nasdaq
- KURA Nasdaq
- Market Cap
- CSTL 456.2M
- KURA 561.9M
- IPO Year
- CSTL 2019
- KURA N/A
- Fundamental
- Price
- CSTL $20.49
- KURA $5.75
- Analyst Decision
- CSTL Strong Buy
- KURA Strong Buy
- Analyst Count
- CSTL 6
- KURA 12
- Target Price
- CSTL $37.67
- KURA $24.50
- AVG Volume (30 Days)
- CSTL 449.7K
- KURA 1.3M
- Earning Date
- CSTL 08-04-2025
- KURA 08-07-2025
- Dividend Yield
- CSTL N/A
- KURA N/A
- EPS Growth
- CSTL N/A
- KURA N/A
- EPS
- CSTL N/A
- KURA N/A
- Revenue
- CSTL $347,083,000.00
- KURA $67,991,000.00
- Revenue This Year
- CSTL N/A
- KURA $109.86
- Revenue Next Year
- CSTL $1.36
- KURA $107.90
- P/E Ratio
- CSTL N/A
- KURA N/A
- Revenue Growth
- CSTL 38.43
- KURA N/A
- 52 Week Low
- CSTL $15.45
- KURA $5.41
- 52 Week High
- CSTL $35.84
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- CSTL 67.41
- KURA 39.74
- Support Level
- CSTL $18.18
- KURA $5.73
- Resistance Level
- CSTL $20.63
- KURA $5.88
- Average True Range (ATR)
- CSTL 0.78
- KURA 0.28
- MACD
- CSTL 0.22
- KURA -0.07
- Stochastic Oscillator
- CSTL 85.79
- KURA 7.51
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.